047920.KQ KOE
HLB Pharmaceutical Co., Ltd
1W: +35.3%
1M: +28.8%
3M: -19.3%
YTD: -38.5%
1Y: -33.5%
3Y: -18.6%
5Y: -30.2%
₩10,010.00 ($7.45)
-1140.00 (-10.22%)
Weekly Expected Move ±24.5%
₩5100
₩7555
₩10010
₩12465
₩14920
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$569M
-91.7% ▼
Capital Expenditures
$7.2B
-133.2% ▼
5Y CAGR: +19.3%
Free Cash Flow
-$6.6B
-277.1% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$2.9B
-150.4% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$13.2B | -$11.8B | -$19.4B | $2.0B | $4.6B |
| Depreciation & Amort. | $3.8B | $4.5B | $5.0B | $5.1B | $4.1B |
| Stock-Based Comp. | $315M | $436M | $543M | $289M | $0 |
| Change in Working Capital | -$6.9B | -$4.5B | -$5.5B | $516M | -$5.1B |
| Other Non-Cash Items | $14.7B | $8.5B | $1.0B | -$1.1B | -$3.0B |
| Operating Cash Flow | -$1.3B | -$2.8B | -$18.3B | $6.8B | $569M |
| — Investing Activities — | |||||
| Capital Expenditures | -$49.5B | -$2.9B | -$4.3B | -$2.8B | -$7.2B |
| Acquisitions (Net) | $178M | $160M | $7.4B | -$600M | -$17.3B |
| Investment Purchases | -$37.5B | -$58.2B | -$20.5B | -$21.7B | -$27.6B |
| Investment Sales | $71.2B | $48.0B | $26.5B | $12.6B | $30.8B |
| Other Investing | -$201M | -$424M | $366M | $247M | -$92M |
| Investing Cash Flow | -$15.8B | -$13.3B | $9.6B | -$12.3B | -$21.3B |
| — Financing Activities — | |||||
| Net Debt Issuance | $10.4B | $20.0B | $4.4B | $10.9B | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$722M | -$852M | -$1.0B | -$1.0B | -$1.2B |
| Financing Cash Flow | $9.6B | $19.1B | $3.8B | $11.1B | $17.9B |
| Net Change in Cash | -$7.4B | $3.1B | -$5.0B | $5.7B | -$2.9B |
| Cash End of Period | $6.6B | $9.7B | $4.8B | $10.5B | $7.6B |
| Free Cash Flow | -$50.8B | -$5.7B | -$22.6B | $3.7B | -$6.6B |